针对瘤表观遗传调节器SETDB1进行瘤治疗
Cheng Peng1, Nini Zhou1, Tengjiang Chen1
1School of life Sciences, Southwest University, No.2 Tiansheng Road., Beibei, Chongqing, China.
Current cancer drug targets
|September 10, 2024
概括
表观遗传变化,包括SETDB1 (SET域分叉的基因素甲基转移酶1),驱动癌症的发展. 本综述探讨了SETDB1的情况.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 表观遗传改变是癌症发展的基础,影响基因表达和细胞转化.
- SETDB1 (SET 域分叉的 基因组 lysine 甲基转移酶 1) 是一个关键的 基因组甲基转移酶,参与异色素蛋白的形成和基因沉默.
- 提高SETDB1表达与各种癌症的预后不佳和低生存率相关.
研究的目的:
- 阐明SETDB1在不同癌症类型中的机制性作用.
- 审查针对SETDB1.1.的表观遗传抑制剂的最新进展.
- 总结一下SETDB1在各种疾病和细胞功能中的参与.
主要方法:
- 关于SETDB1在瘤发生中的功能研究的文献综述.
- 对表观遗传抑制剂及其抗瘤功效的分析.
- 收集关于SETDB1在疾病和细胞生物学中的作用的数据.
主要成果:
- SETDB1促进 heterochromatin 的形成和基因沉默,有助于癌症的进展.
- 高SETDB1表达是许多癌症预后不佳的生物标志物.
- 各种表观遗传抑制剂在向SETDB1驱动的瘤发生方面表现有前途.
结论:
- SETDB1是癌症发展中的关键表观遗传调节剂.
- 用表观遗传抑制剂向SETDB1是一个潜在的治疗策略.
- 对SETDB1的多方面的作用进行进一步的研究是治疗进步的必要条件.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


